115 studies found for:    "Acromegaly"
Show Display Options
Rank Status Study
21 Completed Acute Application of Pegvisomant and Octreotide in Acromegaly
Condition: Acromegaly
Interventions: Drug: pegvisomant;   Drug: combination with somatostatin analogue octreotide;   Drug: combination with dopamine agonist cabergoline
22 Recruiting Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Conditions: Cushing's Disease,;   Acromegaly
Interventions: Drug: Pasireotide s.c.;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin;   Drug: Pasireotide LAR;   Drug: Metformin
23 Active, not recruiting Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Condition: Acromegaly
Interventions: Drug: Pasireotide (SOM230);   Drug: octreotide LAR 30mg;   Drug: lanreotide ATG 120mg
24 Recruiting Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
Condition: Acromegaly
Intervention:
25 Unknown  Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
Conditions: Acromegaly;   Obstructive Sleep Apnea;   Insulin Resistance
Interventions: Device: Continuous positive air pressure device (CPAP);   Other: External nasal dilator adhesive
26 Recruiting Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
Condition: Acromegaly
Intervention: Drug: Sandostatin® LAR
27 Completed
Has Results
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Condition: Acromegaly
Interventions: Drug: Somatuline Autogel (lanreotide acetate);   Behavioral: Home administration
28 Completed Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Condition: Acromegaly
Intervention: Drug: Lanreotide (Autogel formulation)
29 Available An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: Pasireotide long acting release formulation
30 Active, not recruiting Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.
Conditions: Acromegaly;   Surgery
Intervention:
31 Unknown  Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
Conditions: Acromegaly;   Heart Failure;   Hypertrophy, Left Ventricular
Intervention: Drug: pegvisomant
32 Unknown  A Study Examining the Peri- and Post-operative Dynamics of the Growth Hormone (GH) - IGF-1 Axis in Subjects With Acromegaly During the First Year After Surgical Resection
Condition: Acromegaly
Intervention: Other: OGTT
33 Active, not recruiting Efficacy and Safety of Pasireotide LAR in Japanese Patients With Acromegaly or Pituitary Gigantism
Condition: Acromegaly, Pituitary Gigantism
Intervention: Drug: SOM230LAR
34 Completed Physiopathology of Sodium Retention in Acromegaly
Condition: Acromegaly
Intervention: Drug: furosemide
35 Active, not recruiting Brain-gut Interaction in Irradiated Patients With Acromegaly
Condition: Acromegaly
Intervention:
36 Recruiting Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Condition: Acromegaly
Intervention:
37 Completed Prediction of Tumor Shrinkage in Acromegaly
Condition: Acromegaly
Intervention: Drug: Octreotide-LAR
38 Completed Open Label Study of Octreotide Implant in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: octreotide acetate
39 Terminated Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Condition: Acromegaly
Interventions: Drug: Octreotide Implant;   Drug: Sandostatin LAR Depot
40 Recruiting IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly
Condition: Acromegaly
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years